- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Journal: Optimization of a mass spectrometric analytical method for the quality assessment of insulin and its analogs. (Pubmed Central) - Aug 17, 2024
The study results demonstrated that MS is a suitable technique for the analysis of biotechnological compounds like insulin and its analogs. Although the obtained results provide an important information regarding this methodology, further studies are needed to validate this analytical approach and check for its suitability to be used in the regulatory environment.
- |||||||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Reactive Eccrine Syringofibroadenoma: A Case Report of a Rare Disease (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_4433;
Multiple anastomosing cords of benign epithelial cells surrounded by a loose fibrovascular stroma can be seen in the histopathological analysis of lesions. ESFA stains positively with epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) .
- |||||||||| Preclinical, Journal: Assessment of subcutaneously administered insulins using in vitro release cartridge: Medium composition and albumin binding. (Pubmed Central) - Jul 31, 2024
Albumin-binding acylated insulin analogs exhibited rapid disappearance from the cartridge; however, sustained retention was achieved by coupling albumin to the matrix. An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions.
- |||||||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Stressful Dose Steroids: When Should I Worry About Perioperative Adrenal Insufficiency? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_2551;
An in vitro-in vivorelation was established for the non-albumin-binding insulins.The IVR cartridge is flexible with potential in formulation development as shown by the ability to accommodate solutions, suspensions, and in situ forming formulations while tailoring of the system to probe in vivo relevant medium effects and tissue constituent interactions. Medications of significance include 20 mg prednisone po qday for ulcerative colitis, detemir insulin 12 units SQ qday, aspirin 81 mg po qday, empagliflozin, metoprolol, albuterol inhaler prn, tiotropium qd and amlodipine...3.What is the equivalent potency of glucocorticoid and mineralocorticoid effect for this patient
- |||||||||| Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Stressful Dose Steroids: When Should I Worry About Perioperative Adrenal Insufficiency? (126A) - Jun 25, 2024 - Abstract #ASA2024ASA_1591;
Medications of significance include 20 mg prednisone po qday for ulcerative colitis, detemir insulin 12 units SQ qday, aspirin 81 mg po qday, empagliflozin, metoprolol, albuterol inhaler prn, tiotropium qd and amlodipine...3.What is the equivalent potency of glucocorticoid and mineralocorticoid effect for this patient Medications of significance include 20 mg prednisone po qday for ulcerative colitis, detemir insulin 12 units SQ qday, aspirin 81 mg po qday, empagliflozin, metoprolol, albuterol inhaler prn, tiotropium qd and amlodipine...3.What is the equivalent potency of glucocorticoid and mineralocorticoid effect for this patient
- |||||||||| Awiqli (insulin icodec) / Novo Nordisk
Cost-Effectiveness of Insulin Icodec for the Treatment of Type 2 Diabetes (T2D) in Canada (Poster Hall (West A4-B2); 1046) - May 20, 2024 - Abstract #ADA2024ADA_2970;
$45,433 in all analyses, except for the comparison versus IGlar U100 when IIco price is ? IDeg, and versus IGlar U300 when IIco price is = IDeg +10%.At a willingness-to-pay threshold of $50,000/QALY gained, IIco is a cost-effective treatment option for T2D versus once daily basal insulin analogues currently reimbursed in Canada.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Enrollment closed, Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Mar 5, 2024
P3, N=319, Active, not recruiting,
Insulin-na Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Jan 5, 2024
P3, N=264, Recruiting,
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2024 --> Sep 2024 Trial completion date: Apr 2024 --> Apr 2025
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: The effect of insulin analogs in people with type 1 diabetes at increased risk of severe hypoglycemia. (Pubmed Central) - Dec 13, 2023
However, the absolute treatment differences in the reduction of hypoglycemia are even greater in the trials, including people at high risk of hypoglycemia. This emphasizes the importance of including people at high risk of hypoglycemia to assess the full clinical and pharmacoeconomic benefit of new insulins.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - Sep 13, 2023
P3, N=264, Recruiting,
However, insulin detemir was associated with lesser incidence of maternal hypoglycemic events and greater gestational age at delivery, compared to NPH. Trial primary completion date: Aug 2023 --> Dec 2023
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal, HEOR: Changes of health-related quality of life after initiating basal insulin treatment among people with type 2 diabetes. (Pubmed Central) - Sep 1, 2023
Initial insulin regimens of single BI and of basal-bolus (BI included Glargine, Detemir, and Neutral Protamine Hagedorn) accounted for 75.6% and 24.4%, respectively...Basal-bolus has the most significant potential to increase HRQoL, however, the people with diabetes characteristics differ from those initiating BI alone. Further longitudinal cohort study with a longer study period might be necessary to evaluate the certain effect.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal, HEOR, Real-world evidence, Adherence, Real-world: Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100). (Pubmed Central) - Jul 17, 2023
This study compared treatment persistence, treatment adherence, rates of hypoglycemia, and health care resource utilization outcomes in people with type 2 diabetes who either continued treatment with the second-generation BI Gla-300 or switched to a first-generation BI. The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Retrospective data, Journal: Insulin Detemir Versus Glibenclamide in Gestational Diabetes Mellitus: A Retrospective Cohort Study. (Pubmed Central) - Jul 3, 2023
The study showed that continuing with Gla-300 was associated with a lower risk of discontinuing therapy, fewer emergency department visits, and lower hypoglycemia event rates than switching to a first-generation BI. In pregnant women with GDM, glucose control on IDet yielded comparable results as on glibenclamide, except for a significantly lower rate of LGA neonates.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Preclinical, Journal: Probing the mechanism of reduced in vivo potency of insulin detemir. (Pubmed Central) - Jun 19, 2023
No significant differences were detected with co-infusions of HI with either bacitracin or vehicle. A large proportion of NRMD of IDet which can be inhibited by bacitracin may partly explain the reduced potency of IDet observed in rats and likely also in man.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Clinical guideline, Review, Journal: Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline. (Pubmed Central) - Jun 19, 2023
A large proportion of NRMD of IDet which can be inhibited by bacitracin may partly explain the reduced potency of IDet observed in rats and likely also in man. The objective of this study was to provide recommendations regarding effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins (glargine U-300, degludec U-100, glargine U-100, detemir, and insulin protamine Hagedorn) in insulin-na
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion, Trial completion date: CF-IDEA: Cystic Fibrosis - Insulin Deficiency, Early Action (clinicaltrials.gov) - May 31, 2023
P3, N=100, Completed,
The objective of this study was to provide recommendations regarding effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins (glargine U-300, degludec U-100, glargine U-100, detemir, and insulin protamine Hagedorn) in insulin-na Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion: DEES: Detemir Energy Expenditure Study (clinicaltrials.gov) - May 31, 2023
P4, N=30, Completed,
Active, not recruiting --> Completed | Trial completion date: Jun 2023 --> Feb 2023 Unknown status --> Completed
- |||||||||| Insulatard (isophane insulin) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Novolin R (recombinant human insulin) / Novo Nordisk
Journal: ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS CHILDREN WITH DIABETES MELLIUS TYPE 1 USING DIFFERENT TYPES OF INSULIN PREPARATIONS. (Pubmed Central) - May 15, 2023
Group 1 included 20 children who used Insulin human (Insulatard), group 2 included 15 children using insulin Glargine, and group 3 included 14 children using insulin Detemir...Those using Insulin human (Insulatard) used Human insulin (rDNA, Actrapid) in addition...However, no such relationship between Glargine, body mass and height was recorded. It was a negative correlation between its dose Glargine with glycohemoglobin and also between glucose and cholesterol using Glargine.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Misdiagnosing Latent Autoimmune Diabetes Mellitus in Adults: A Case Report (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_191;
Type 1 diabetes mellitus or autoimmune diabetes mellitus should always be ruled out if the clinical picture does not match with type 2 Diabetes Mellitus or in a relatively young patient. Our case aims to increase awareness of Autoimmune Polyendocrine syndrome, which occurs as a result of loss of immune tolerance, leading to impairment of multiple endocrine glands.
- |||||||||| Afrezza (recombinant human insulin inhalation) / MannKind
Trial primary completion date, Combination therapy: Afrezza (clinicaltrials.gov) - May 8, 2023
P3, N=264, Recruiting,
This finding provides important reassurance regarding the safety of long-acting insulin analogues with respect to incident DR. Trial primary completion date: Apr 2023 --> Aug 2023
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Total Chemical Synthesis of Palmitoyl-Conjugated Insulin. (Pubmed Central) - Apr 24, 2023
The palmitoyl-insulin is shown to be structurally similar to insulin and biologically active both in vitro and in vivo. Importantly, unlike native insulin, palmitoyl-insulin is slow and long-acting.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: Insulin Therapy in Small Animals, Part 1: General Principles. (Pubmed Central) - Apr 11, 2023
For a formulation to be an effective and safe basal insulin, its action should be roughly the same every hour of the day. Currently, only insulin glargine U300 and insulin degludec meet this standard in dogs, whereas in cats, insulin glargine U300 is the closest option.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Review, Journal: Insulin Therapy in Small Animals, Part 3: Dogs. (Pubmed Central) - Apr 11, 2023
In most dogs, good control of clinical signs is achieved when using a basal insulin alone. In a small minority, bolus insulin at the time of at least one meal per day may be added to optimize glycemic control.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi
Journal: Insulin analogs in the treatment of type II diabetes and future perspectives. (Pubmed Central) - Mar 28, 2023
This review explores the currently available insulin analogs, their clinical implications, pharmacokinetics (PK), pharmacodynamics (PD), safety profile, and cost-effectiveness. We also discuss the future developments in the management of T2DM, especially the scientific advancements surrounding the novel insulin formulations, including the biosimilar insulin, and the innovative insulin delivery methods, such as oral and inhaled insulin.
- |||||||||| Levemir (insulin detemir rDNA origin) / Novo Nordisk
Trial completion date, Trial primary completion date: IDIOM: Insulin Detemir in Obesity Management (clinicaltrials.gov) - Feb 13, 2023
P=N/A, N=240, Active, not recruiting,
Detemir is useful in diabetic dogs with other comorbidities and can be considered an alternative treatment in poorly controlled diabetic dogs. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Clinical Evidence and Practice-Based Guidelines on the Utility of Basal insulin combined Oral therapy (metformin and glimepiride) in the current era. (Pubmed Central) - Jan 11, 2023
Compared with other long-acting insulin analogues (insulin glargine and insulin detemir), insulin degludec was associated with a significantly decreased FPG, with lower prevalences of overall and nocturnal hypoglycemia. These current clinical practice guidelines highlight the efficacy and safety of basal insulin combination therapy with various available basal insulins including neutral protamine hagedorn, detemir, glargine and degludec in addition to metformin and glimepiride therapy.
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal, Combination therapy, Head-to-Head: Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. (Pubmed Central) - Jan 10, 2023
P3
These current clinical practice guidelines highlight the efficacy and safety of basal insulin combination therapy with various available basal insulins including neutral protamine hagedorn, detemir, glargine and degludec in addition to metformin and glimepiride therapy. In pregnant women with type 1 diabetes, degludec was found to be non-inferior to detemir.
- |||||||||| 100 years with insulin. Implementation of analogs and technology in our environment (Rome, Italy) - Nov 13, 2022 - Abstract #ESPE2022ESPE_812;
Of the 6 pumps, they use lispro (4/6), aspartic (1/6) and another glulisine (1/6) Of the MDIs, as slow analogs NPH 0/65, detemir 12/65 (85% are <6 years), U100 10/65, U300 35/65 liraglutide 8/65...Of the MDIs, such as fast analogues è Actrapid 0/65, lispro 30/65 (1 U200 off labell per dose), aspartic 10/65, ultrafast (15/65) and glulisine 10/65 The indication has been for age, comfort, dose / need for stockings and a pen for this purpose and switch due to poor adjustment of the previous analog...There was no impediment by medical inspection in any prescription except in 1 case (belonging to another health area) with BAQSIMI Previous severe hypoglycemia with previous loss of consciousness in <5% of cases (0.03 patient / year cases)... We assume that this study may have some shortcomings due to the size of the sample, but our study demonstrates the implementation of the most modern analogs in the office, of measurement technology, but the need to advance in the use of insulin pumps.
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Levemir (insulin detemir rDNA origin) / Novo Nordisk
Journal: Site-Specific Albumin-Selective Ligation to Human Serum Albumin under Physiological Conditions. (Pubmed Central) - Nov 10, 2022
Furthermore, these RAEs are orthogonal to the maleimide-based conjugation strategy for Cys34 of HSA. Together, these attributes make the RAEs the promising leads to further develop in vitro and in vivo HSA bioconjugation strategies for numerous biomedical applications.
|
